Jaguar Health Inc reports results for the quarter ended March 31 - Earnings Summary
16/05/2025 20:04
Jaguar Health Inc JAGX.OQ reported a quarterly adjusted loss of $16.70 per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-105.00. The lone analyst forecast for the quarter was for a loss of $18.00 per share. Revenue fell 5.8% to $2.21 million from a year ago; analysts expected $2.82 million. Jaguar Health Inc's reported EPS for the quarter was a loss of $16.70. Jaguar Health Inc shares had risen by 15.5% this quarter and lost 78.2% so far this year. FORECAST CHANGES The mean earnings estimate of analysts was unchanged in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy." Wall Street's median 12-month price target for Jaguar Health Inc is $16.00 This summary was machine generated from LSEG data May 16 at 07:04 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -18.00 | -16.70 | Beat |
| Dec. 31 2024 | -18.50 | -0.34 | Beat |
| Sep. 30 2024 | -59.25 | -26.25 | Beat |
| Jun. 30 2024 | -30.00 | -1.01 hundred | Missed |